GlassScriptPhysician profile
Charles W Lin
NPI 1982719225
$5,271.75
in general payments reported to CMS, 2019-2025
14 companies · $430 in 2025
The $430 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $363 · 2021: $387 · 2022: $921 · 2023: $1,054 · 2024: $1,161 · 2025: $430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,644.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,845.16 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amarin Pharma, INC. | $430.85 | 2019 | |
| Abbott Laboratories | $389.89 | 2019-2022 | |
| Esperion Therapeutics, INC. | $375.00 | 2021-2023 | Nexlizet, Nexletol |
| Allergan, INC. | $255.54 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.73 | 2022 | |
| Gilead Sciences, INC. | $173.90 | 2019-2025 | |
| Amgen INC. | $136.34 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $124.95 | 2020 | |
| Ironwood Pharmaceuticals, INC | $119.17 | 2022 | |
| Merck Sharp & Dohme LLC | $100.00 | 2019 | |
| Cequr Corporation | $96.06 | 2024 | Cequr Simplicity |
| Beckman Coulter, INC. | $12.12 | 2021 | |
| Endo Pharmaceuticals INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.